Analyst consensus rating
vTv Therapeutics Analyst Rating: Strong Buy
Direct answer
vTv Therapeutics's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $54.71.
Forecast evidence checked September 8, 2026.
Get free vTv Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $32.79
- Average price target
- $54.71
- High price target
- $67.00
- Low price target
- $42.00
- Low target gap
- +28.1%
- Target upside
- +66.9%
- High target gap
- +104.3%
- Target range width
- 76.2%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for vTv Therapeutics?
vTv Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $54.71.
How far are vTv Therapeutics's low and high targets from the recorded price?
The low target implies +28.1%, while the high target implies +104.3%.
How many analysts are included in vTv Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is vTv Therapeutics's target upside or downside calculated?
The average target of $54.71 is divided by the recorded price of $32.79, then one is subtracted to produce +66.9%. This does not guarantee a future return.
When was vTv Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.